Published in Curr Rheumatol Rep on December 01, 2014
Improving care delivery and outcomes in pediatric rheumatic diseases. Curr Opin Rheumatol (2016) 0.79
Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. Pediatr Rheumatol Online J (2016) 0.75
Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography. Pediatr Rheumatol Online J (2016) 0.75
Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. J Pediatr (2017) 0.75
Tumoral Calcinosis as an Initial Complaint of Juvenile-Onset Amyopathic Dermatomyositis. Ann Dermatol (2016) 0.75
Calcinosis Universalis of the Elbow: A Rare Case with Classical Presentation. Case Rep Orthop (2015) 0.75
Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review. Clin Rev Allergy Immunol (2017) 0.75
Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 18.52
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
Heterotopic ossification: a review. Skeletal Radiol (2005) 2.86
Calcinosis in rheumatic diseases. Semin Arthritis Rheum (2005) 2.67
Calcifying disorders of the skin. J Am Acad Dermatol (1995) 2.42
Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol (2011) 1.95
Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol (2002) 1.88
TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum (2000) 1.71
Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol (2002) 1.62
Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum (2008) 1.60
Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum (2012) 1.55
Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage. Dermatol Surg (2008) 1.47
Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol (2008) 1.43
Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis (2003) 1.42
Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev (2013) 1.37
Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum (2009) 1.37
Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res (1998) 1.36
New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr (2001) 1.33
Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum (2009) 1.30
The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) (2006) 1.25
Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum (2006) 1.23
Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) (2010) 1.23
Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol (2011) 1.22
Matrix proteins and mineralization: an overview. Connect Tissue Res (1996) 1.21
The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) (1992) 1.20
Case 104: calcinosis in juvenile dermatomyositis. Radiology (2007) 1.19
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.19
Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol (2009) 1.18
Expanding role of bisphosphonate therapy in children. J Pediatr (1999) 1.18
Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho). Best Pract Res Clin Rheumatol (2011) 1.13
Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am (2002) 1.12
Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther (2012) 1.12
Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol (2009) 1.12
Extracellular calcium elicits a chemokinetic response from monocytes in vitro and in vivo. J Clin Invest (2000) 1.11
The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.10
Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) (2009) 1.09
Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) (2008) 1.08
Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol (1998) 1.07
Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) (2008) 1.07
Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol (2009) 1.04
Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol (2012) 1.04
Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum (2010) 1.04
Patterns of calcification in childhood dermatomyositis. AJR Am J Roentgenol (1984) 1.04
Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol (2011) 1.04
Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) (2008) 1.02
Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch Dermatol (1988) 1.00
Parallel regulation of extracellular ATP and inorganic pyrophosphate: roles of growth factors, transduction modulators, and ANK. Connect Tissue Res (2010) 1.00
Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol (2011) 0.98
Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res (Hoboken) (2014) 0.98
Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol (1993) 0.97
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther (2012) 0.97
Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study. Pediatr Rheumatol Online J (2014) 0.97
Role of activated macrophage and inflammatory cytokines in the development of calcinosis in juvenile dermatomyositis. Rheumatology (Oxford) (2013) 0.94
Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol (2005) 0.93
A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol (2010) 0.93
Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. Arthritis Rheum (2009) 0.92
Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol (2010) 0.91
Zebrafish enpp1 mutants exhibit pathological mineralization, mimicking features of generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE). Dis Model Mech (2014) 0.91
Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. Arthritis Res Ther (2009) 0.90
High frequency of calcinosis in juvenile dermatomyositis: a risk factor study. Rev Bras Reumatol (2012) 0.90
Bisphosphonates and atherosclerosis. Gen Pharmacol (2000) 0.89
Topical sodium thiosulfate therapy for leg ulcers with dystrophic calcification. Arch Dermatol (2008) 0.88
Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol (2010) 0.88
Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum (2000) 0.87
Therapy of calcinosis universalis complicating adult dermatomyositis. Acta Reumatol Port (2013) 0.86
Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient. Pediatr Nephrol (2009) 0.86
Anticalcification and antiresorption effects of bisacylphosphonates. Bone (1995) 0.85
Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? Ann Rheum Dis (1998) 0.85
Scintigraphic evaluation of calcinosis in juvenile dermatomyositis with Tc-99m MDP. Clin Nucl Med (2000) 0.85
Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) (2014) 0.85
Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol (1996) 0.85
Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine (2009) 0.84
Panniculitis, infection, and dermatomyositis: case and literature review. Clin Rheumatol (2009) 0.84
Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Curr Rheumatol Rep (2006) 0.83
Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol (2006) 0.83
Vertebrate mineralized matrix proteins: structure and function. Connect Tissue Res (1996) 0.83
Drug-induced dermatomyositis after zoledronic acid. Australas J Dermatol (2011) 0.83
Ultrastructural study of calcinosis universalis with dermatomyositis. J Cutan Pathol (1986) 0.83
Bisphosphonate use in conditions other than osteoporosis. Ann N Y Acad Sci (2010) 0.83
It ANKH necessarily so. J Clin Endocrinol Metab (2011) 0.82
Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol (1986) 0.82
Successful treatment of severe iatrogenic calcinosis cutis with intravenous sodium thiosulfate in a child affected by T-acute lymphoblastic leukemia. Pediatr Dermatol (2009) 0.82
Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol (1998) 0.82
Images in rheumatology. Severe adult-onset calcinosis in a patient with a history of juvenile dermatomyositis. J Rheumatol (2010) 0.81
Failure of disodium etidronate in calcinosis due to dermatomyositis and scleroderma. N Engl J Med (1974) 0.81
Possible zoledronic acid-induced dermatomyositis. Clin Exp Dermatol (2011) 0.81
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr (2012) 0.81
Extensive calcinosis cutis with systemic lupus erythematosus. Arch Dermatol (1990) 0.81
Dramatic diminution of a large calcification treated with topical sodium thiosulfate. Arthritis Rheum (2012) 0.80
Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis. Pediatr Rheumatol Online J (2010) 0.80
Calcinosis in juvenile dermatomyositis: a possible role for the vitamin K-dependent protein matrix Gla protein. Rheumatology (Oxford) (2008) 0.79
Plain radiography is effective for the detection of calcinosis cutis occurring in association with autoimmune connective tissue disease. Br J Dermatol (2014) 0.79
Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch Dermatol (2009) 0.79
Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rheumatol (2001) 0.78
Dermatomyositis with universal calcinosis. A histopathological and electron optic study. J Cutan Pathol (1979) 0.77
Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients. J Transplant (2014) 0.77
Colchicine modulates expression of pro-inflammatory genes in neutrophils from patients with familial Mediterranean fever and healthy subjects. J Biol Regul Homeost Agents (2013) 0.77
Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy. Joint Bone Spine (2012) 0.77
Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol (2012) 0.77
Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis. J Am Acad Dermatol (2012) 0.76
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum (2004) 2.31
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) (2003) 2.18
Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet (2008) 2.16
Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet (2012) 2.15
A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum (2006) 1.93
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum (2005) 1.75
Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum (2008) 1.60
HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum (2003) 1.46
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) (2006) 1.39
Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) (2010) 1.32
Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol (2009) 1.27
Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum (2006) 1.24
Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) (2008) 1.22
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.19
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine (Baltimore) (2005) 1.18
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis (2012) 1.15
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum (2008) 1.09
The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2010) 1.05
Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr (2006) 1.04
Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum (2002) 1.01
HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum (2006) 1.00
Diagnostic criteria for polymyositis and dermatomyositis. Lancet (2003) 0.97
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol (2014) 0.97
Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J (2009) 0.96
Walking ability and its relationship to lower-extremity muscle strength in children with idiopathic inflammatory myopathies. Arch Phys Med Rehabil (2004) 0.96
Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J (2009) 0.95
Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum (2008) 0.94
Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis (2006) 0.93
Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum (2008) 0.93
Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. Arthritis Res Ther (2011) 0.92
Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis Rheum (2007) 0.91
Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum (2007) 0.91
Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. Arthritis Res Ther (2009) 0.90
Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. Ann Rheum Dis (2012) 0.90
Parvovirus B19 and onset of juvenile dermatomyositis. JAMA (2005) 0.89
2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken) (2013) 0.86
Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum (2004) 0.86
Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum (2013) 0.85
Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) (2014) 0.82
Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. Open Rheumatol J (2012) 0.82
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr (2012) 0.81
Metabolic abnormalities and cardiovascular risk factors in children with myositis. J Pediatr (2009) 0.81
Parents' perception of self-advocacy of children with myositis: an anonymous online survey. Pediatr Rheumatol Online J (2011) 0.80
Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. BMC Musculoskelet Disord (2014) 0.80
Decreased aerobic capacity in children with juvenile dermatomyositis. Arthritis Rheum (2002) 0.79
Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases. Arthritis Res Ther (2011) 0.79
Fitness as a determinant of the oxygen uptake/work rate slope in healthy children and children with inflammatory myopathy. Can J Appl Physiol (2003) 0.79
Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface? Arthritis Rheum (2010) 0.77
Confusion concerning multiple versions of the childhood myositis assessment scale. Arthritis Care Res (Hoboken) (2014) 0.77
Clinical research networks: a step towards evidence-based practice in pediatric rheumatology. Nat Clin Pract Rheumatol (2007) 0.77
Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. Arthritis Care Res (Hoboken) (2013) 0.76
On Determining the Effects of Therapy on Disease Damage in Non- randomized Studies with Multiple Treatments: A study of Juvenile Myositis. Commun Stat Theory Methods (2009) 0.75
Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et al. Arthritis Rheum (2008) 0.75
Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. J Rheumatol (2015) 0.75
Post-zygotic and inter-individual structural genetic variation in a presumptive enhancer element of the locus between the IL10Rβ and IFNAR1 genes. PLoS One (2013) 0.75
Developing international consensus on measures of improvement for patients with myositis. Stat Methods Med Res (2007) 0.75
Systemic lupus erythematosus, bone health, and osteoporosis. Curr Opin Endocrinol Diabetes Obes (2015) 0.75